Sodium Palmitate
(Synonyms: 棕榈酸钠,Hexadecanoic acid sodium salt, Palmitic acid sodium salt ) 目录号 : GC19521
棕榈酸钠（Sodium palmitate）是一种常见的饱和脂肪酸，在脂肪酸合成过程中产生。
Cas No.:408-35-5
Sample solution is provided at 25 µL, 10mM.
Sodium palmitate is a common saturated fatty acid produced during the process of fatty acid synthesis. In the field of life science research, sodium palmitate is primarily used for studying cell metabolism, lipid research, and as a nutritional supplement in cell culture. Sodium palmitate can enhance lipogenesis and lipid droplet formation in various cell lines, and it is used to establish cell models of lipid droplet accumulation.
In vitro, Sodium palmitate (0.1, 0.25, or 0.5 mM; 12-72 h) can increase the mRNA levels of Notch1, -2, and -4 in LX2, Huh7, and MIHA liver cell lines[1]. Sodium palmitate can induce the expression of Glucose Regulated Protein 78 (GRP 78) and CCAAT/Enhancer Binding Protein Homologous Protein (CHOP) in mouse granule cells[2]. Moreover, treating LO2 cells with 100 µmol/l sodium palmitate for 48 hours significantly inhibits cell viability, and this concentration and incubation time can be used as a model of lipotoxicity in experiments[3].
References:
[1] Wen-Jin Ding, et al. Expression of Notch family is altered in non‑alcoholic fatty liver disease. Mol Med Rep. 2020 Sep;22(3):1702-1708.
[2] Harada H, et al. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. Anticancer Res. 2002 Sep-Oct;22(5):2587-90.
[3] Ma, Cheng, Yuan, et al. Lipid storage droplet protein 5 reduces sodium palmitateinduced lipotoxicity in human normal liver cells by regulating lipid metabolismrelated factors[J]. Molecular Medicine Reports, 2019, 20(2):879-886.
棕榈酸钠（Sodium palmitate）是一种常见的饱和脂肪酸，在脂肪酸合成过程中产生。棕榈酸钠在生命科学研究领域主要用于研究细胞代谢、脂质研究、以及作为细胞培养中的营养补充物。棕榈酸钠可增强各种细胞系中的脂肪生成和细胞脂肪变性，用于建立细胞脂肪变性模型。
在体外，棕榈酸钠(0.1、0.25 或 0.5 mM；12-72 h) 可增加 LX2、Huh7 和 MIHA 肝细胞系中Notch1、-2和-4的mRNA 水平[1]。棕榈酸钠可诱导小鼠颗粒细胞中葡萄糖调节蛋白78（GRP 78）和CCAAT/增强子结合蛋白同源蛋白（CHOP）的表达[2]。此外，用100 µmol/l棕榈酸钠处理LO2细胞48h，细胞活力显著受到抑制，该浓度和孵育时间可在实验中用作脂毒性模型[3]。
|
Cell experiment [1]: |
|
|
Cell lines |
LX2, Huh7 and MIHA liver cell lines |
|
Preparation method |
PA was dissolved in DMEM containing 1% BSA and filtered through a 0.22-µm filter, then added to the cells and incubated at 37°C to 80% confluency in DMEM with 10% FBS. The concentrations of PA used were 0.1, 0.25 or 0.5 mM, and the incubation times were 12–72 h. |
|
Reaction Conditions |
0.1, 0.25, 0.5 mM;12-72 h |
|
Applications |
Sodium palmitate can increase the mRNA levels of Notch1, -2, and -4 in LX2, Huh7, and MIHA liver cell lines. |
|
Cell experiment [2]: |
|
|
Cell lines |
LO2 cells |
|
Preparation method |
cells were treated with sodium palmitate at 25, 50, 75, 100, 125 or 150 µmol/L and incubated for 12, 24 or 48 h. Following incubation, CCK-8 reagent was added into each well and the cells were incubated in humidified environment with 5% CO2 at 37°C for 2 h. |
|
Reaction Conditions |
25, 50, 75, 100, 125 or 150 µmol/L; 12, 24 or 48 h |
|
Applications |
Treating LO2 cells with greater than 100 µmol/l sodium palmitate for 48 h significantly inhibited cell viability and can be used as a lipotoxicity model in experiments. |
|
References: [1] Wen-Jin Ding, et al. Expression of Notch family is altered in non‑alcoholic fatty liver disease. Mol Med Rep. 2020 Sep;22(3):1702-1708. [2]Ma, Cheng, Yuan, et al. Lipid storage droplet protein 5 reduces sodium palmitateinduced lipotoxicity in human normal liver cells by regulating lipid metabolismrelated factors[J]. Molecular Medicine Reports, 2019, 20(2):879-886. |
|
| Cas No. | 408-35-5 | SDF | |
| 别名 | 棕榈酸钠,Hexadecanoic acid sodium salt, Palmitic acid sodium salt | ||
| 分子式 | C16H31NaO2 | 分子量 | 278.41 |
| 溶解度 | Soluble in methanol; DMSO: 8.33 mg/mL (29.92 mM; ultrasonic and warming and adjust pH to 4 with 1M HCl and heat to 60°C) | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5918 mL | 17.9591 mL | 35.9183 mL |
| 5 mM | 0.7184 mL | 3.5918 mL | 7.1837 mL |
| 10 mM | 0.3592 mL | 1.7959 mL | 3.5918 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
